Literature DB >> 28461310

Structure of the Enterovirus 71 3C Protease in Complex with NK-1.8k and Indications for the Development of Antienterovirus Protease Inhibitor.

Yaxin Wang1, Lin Cao1, Yangyang Zhai1, Zheng Yin1, Yuna Sun2, Luqing Shang3.   

Abstract

Hand-foot-and-mouth disease (HFMD), caused by enterovirus, is a threat to public health worldwide. To date, enterovirus 71 (EV71) has been one of the major causative agents of HFMD in the Pacific-Asia region, and outbreaks with EV71 cause millions of infections. However, no drug is currently available for clinical therapeutics. In our previous works, we developed a set of protease inhibitors (PIs) targeting the EV71 3C protease (3Cpro). Among these are NK-1.8k and NK-1.9k, which have various active groups and high potencies and selectivities. In the study described here, we determined the structures of the PI NK-1.8k in complex with wild-type (WT) and drug-resistant EV71 3Cpro Comparison of these structures with the structure of unliganded EV71 3Cpro and its complex with AG7088 indicated that the mutation of N69 to a serine residue destabilized the S2 pocket. Thus, the mutation influenced the cleavage activity of EV71 3Cpro and the inhibitory activity of NK-1.8k in an in vitro protease assay and highlighted that site 69 is an additional key site for PI design. More information for the optimization of the P1' to P4 groups of PIs was also obtained from these structures. Together with the results of our previous works, these in-depth results elucidate the inhibitory mechanism of PIs and shed light to develop PIs for the clinical treatment of infections caused by EV71 and other enteroviruses.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  EV71; crystal structure; inhibitor; mechanism; protease

Mesh:

Substances:

Year:  2017        PMID: 28461310      PMCID: PMC5487676          DOI: 10.1128/AAC.00298-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  29 in total

1.  Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes.

Authors:  D A Matthews; P S Dragovich; S E Webber; S A Fuhrman; A K Patick; L S Zalman; T F Hendrickson; R A Love; T J Prins; J T Marakovits; R Zhou; J Tikhe; C E Ford; J W Meador; R A Ferre; E L Brown; S L Binford; M A Brothers; D M DeLisle; S T Worland
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

2.  Crystal structure of human enterovirus 71.

Authors:  Pavel Plevka; Rushika Perera; Jane Cardosa; Richard J Kuhn; Michael G Rossmann
Journal:  Science       Date:  2012-03-01       Impact factor: 47.728

3.  Enterovirus 71 VPg uridylation uses a two-molecular mechanism of 3D polymerase.

Authors:  Yuna Sun; Yaxin Wang; Chao Shan; Cheng Chen; Peng Xu; Mohan Song; Honggang Zhou; Cheng Yang; Wenbo Xu; Pei-Yong Shi; Bo Zhang; Zhiyong Lou
Journal:  J Virol       Date:  2012-10-10       Impact factor: 5.103

4.  An adenosine nucleoside analogue NITD008 inhibits EV71 proliferation.

Authors:  Luqing Shang; Yaxin Wang; Jie Qing; Bo Shu; Lin Cao; Zhiyong Lou; Peng Gong; Yuna Sun; Zheng Yin
Journal:  Antiviral Res       Date:  2014-10-23       Impact factor: 5.970

5.  Peptidyl aldehyde NK-1.8k suppresses enterovirus 71 and enterovirus 68 infection by targeting protease 3C.

Authors:  Yaxin Wang; Ben Yang; Yangyang Zhai; Zheng Yin; Yuna Sun; Zihe Rao
Journal:  Antimicrob Agents Chemother       Date:  2015-02-17       Impact factor: 5.191

6.  Crystal structure of enterovirus 71 RNA-dependent RNA polymerase complexed with its protein primer VPg: implication for a trans mechanism of VPg uridylylation.

Authors:  Cheng Chen; Yaxin Wang; Chao Shan; Yuna Sun; Peng Xu; Honggang Zhou; Cheng Yang; Pei-Yong Shi; Zihe Rao; Bo Zhang; Zhiyong Lou
Journal:  J Virol       Date:  2013-03-13       Impact factor: 5.103

7.  Design, synthesis, and evaluation of 3C protease inhibitors as anti-enterovirus 71 agents.

Authors:  Chih-Jung Kuo; Jiun-Jie Shie; Jim-Min Fang; Guei-Rung Yen; John T-A Hsu; Hun-Ge Liu; Sung-Nain Tseng; Shih-Cheng Chang; Ching-Yin Lee; Shin-Ru Shih; Po-Huang Liang
Journal:  Bioorg Med Chem       Date:  2008-06-13       Impact factor: 3.641

8.  Crystal structure of human enterovirus 71 3C protease.

Authors:  Sheng Cui; Jing Wang; Tingting Fan; Bo Qin; Li Guo; Xiaobo Lei; Jianwei Wang; Meitian Wang; Qi Jin
Journal:  J Mol Biol       Date:  2011-03-17       Impact factor: 5.469

9.  MolProbity: all-atom structure validation for macromolecular crystallography.

Authors:  Vincent B Chen; W Bryan Arendall; Jeffrey J Headd; Daniel A Keedy; Robert M Immormino; Gary J Kapral; Laura W Murray; Jane S Richardson; David C Richardson
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2009-12-21

10.  Phaser crystallographic software.

Authors:  Airlie J McCoy; Ralf W Grosse-Kunstleve; Paul D Adams; Martyn D Winn; Laurent C Storoni; Randy J Read
Journal:  J Appl Crystallogr       Date:  2007-07-13       Impact factor: 3.304

View more
  4 in total

1.  Enterovirus A71 antivirals: Past, present, and future.

Authors:  Jun Wang; Yanmei Hu; Madeleine Zheng
Journal:  Acta Pharm Sin B       Date:  2021-08-20       Impact factor: 14.903

2.  4-Iminooxazolidin-2-One as a Bioisostere of Cyanohydrin Suppresses EV71 Proliferation by Targeting 3Cpro.

Authors:  Binghong Xu; Meijun Liu; Sen Ma; Yuying Ma; Si Liu; Luqing Shang; Cheng Zhu; Sheng Ye; Yaxin Wang
Journal:  Microbiol Spectr       Date:  2021-11-17

3.  Molecular docking study of various Enterovirus-A71 3C protease proteins and their potential inhibitors.

Authors:  Tran Thao Vy Le; Phuc-Chau Do
Journal:  Front Microbiol       Date:  2022-09-29       Impact factor: 6.064

4.  Computational Screening of Newly Designed Compounds against Coxsackievirus A16 and Enterovirus A71.

Authors:  Amita Sripattaraphan; Kamonpan Sanachai; Warinthorn Chavasiri; Siwaporn Boonyasuppayakorn; Phornphimon Maitarad; Thanyada Rungrotmongkol
Journal:  Molecules       Date:  2022-03-15       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.